

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 March 2006 (30.03.2006)

PCT

(10) International Publication Number
WO 2006/033007 A3

(51) International Patent Classification:

C07D 487/06 (2006.01) **A61P 35/00** (2006.01)
A61K 31/55 (2006.01) **A61P 25/00** (2006.01)

(21) International Application Number:

PCT/IB2005/002941

(22) International Filing Date:

12 September 2005 (12.09.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/612,459 22 September 2004 (22.09.2004) US
60/679,296 9 May 2005 (09.05.2005) US

(71) Applicants (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US). **CANCER RESEARCH TECHNOLOGY LTD.** [GB/GB]; Sardinia House, Sardinia Street, London, WC2A 3NL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIU, Jia** [CN/US]; Agouron Pharmaceuticals, Inc., a Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **NAY-YAR, Naresh** [IN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **GUO, Ming** [US/US]; 13835 Carmel Ridge Road, San Diego, CA 92128 (US). **WU, Zhen-Ping** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **BORER, Bennett, Chaplin** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **SRIRANGAM, Aparna, Nadig** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **MITCHELL, Mark, Bryan** [GB/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego,

CA 92121 (US). **LI, Yi** [CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **CHU, Jan-Jon** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

2 November 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYMORPHIC AND AMORPHOUS FORMS OF THE PHOSPHATE SALT OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE



(I)

condition such as cancer.

(57) Abstract: The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by formula (1), and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease